Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity. This proof of concept study will compare the test dentifrice with three other treatment groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

NCT01831817

Dentinal Hypersensitivity

COMPLETED PHASE2

Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

NCT02832375

Dentin Sensitivity

COMPLETED PHASE3

Assessment of the Efficacy of an Experimental Occlusion Technology Dentifrice in Dentinal Hypersensitivity

NCT02861664

Dentin Sensitivity

COMPLETED NA

The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity

NCT01592864

Dentine Hypersensitivity

COMPLETED PHASE3

The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

NCT02612064

Dentin Sensitivity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a single center, eight week, randomized, controlled, examiner blind, four treatment arm, parallel design, stratified (by maximum baseline Schiff Sensitivity Score of the two selected test teeth), exploratory study in participants with at least two sensitive teeth that meet all the criteria at the Screening and Baseline visit. Participants will be assessed at Baseline, four and eight weeks to monitor clinical efficacy and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dentine Hypersensitivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5% calcium sodium phosphosilicate/sodium monofluorophosphate

Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).

Group Type EXPERIMENTAL

5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

Intervention Type DRUG

Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

0% calcium sodium phosphosilicate/sodium monofluorophosphate

Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

Group Type ACTIVE_COMPARATOR

0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice

Intervention Type DRUG

Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

Sodium monofluorophosphate

Dentifrice containing 1000 ppmF as sodium monofluorophosphate

Group Type ACTIVE_COMPARATOR

Sodium monofluorophosphate dentifrice

Intervention Type DRUG

Dentifrice containing 1000 ppmF as sodium monofluorophosphate

Sodium fluoride

Dentifrice containing 1100 ppmF as sodium fluoride

Group Type ACTIVE_COMPARATOR

Sodium fluoride dentifrice

Intervention Type DRUG

Dentifrice containing 1100 ppmF as sodium fluoride

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

Intervention Type DRUG

0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice

Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

Intervention Type DRUG

Sodium monofluorophosphate dentifrice

Dentifrice containing 1000 ppmF as sodium monofluorophosphate

Intervention Type DRUG

Sodium fluoride dentifrice

Dentifrice containing 1100 ppmF as sodium fluoride

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants between 18 and 55 years of age, in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity are required for entry into the study
2. Participants will be required to have at least four teeth with facial/cervical erosion, abrasion and/or gingival recession which respond to qualifying evaporative (air) assessment at the Screening visit and have at least two teeth (incisors, canines or pre-molars) demonstrating signs of sensitivity, measured by qualifying tactile threshold (Yeaple ≤ 20 gram (g)) and evaporative (air) (Schiff Sensitivity Score ≥ 2) assessments at the Baseline visit

Exclusion Criteria

1. Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
2. Breast-feeding: Women who are breast-feeding.
3. Medical History: a) Chronic debilitating disease is present b) Chronic disease or other condition is present that is associated with intermittent episodes or constant daily pain, such as arthritis, low back pain, dysmenorrhea, etc.
4. Medications: Daily doses of medication, which in the opinion of the investigator, might interfere with the perception of pain, are being taken. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, mood-altering and anti-inflammatory drugs.
5. Dentition Exclusions: a) Sensitive teeth not expected to respond to treatment with an over-the- counter dentifrice in the opinion of the investigator. b) Teeth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns, orthodontic bands, extensive caries or cracked enamel. Sensitive teeth with contributing etiologies other than erosion, abrasion or recession of exposed dentine. c) Dental professional hygiene (includes dental prophylaxis, irrigation, and intensive anti-microbial/anti-biotic therapy) within 14 days of the screening visit. d) Presence of dental implants. e) Lip or tongue piercings. f) Periodontal surgical history within the past 6 months or have been scaled /root planed within the past 3 months.
6. Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
7. Clinical Study/Experimental Medication: a) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit b) Previous participation in this study.
8. Other: Any subject who in the opinion of the investigator, should not participate in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No